Cargando…

The Paradigm Change of IL-33 in Vascular Biology

In this review, we focus on the actual understanding of the role of IL-33 in vascular biology in the context of the historical development since the description of IL-33 as a member of IL-1 superfamily and the ligand for ST2 receptor in 2005. We summarize recent data on the biology, structure and si...

Descripción completa

Detalles Bibliográficos
Autores principales: Demyanets, Svitlana, Stojkovic, Stefan, Huber, Kurt, Wojta, Johann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707059/
https://www.ncbi.nlm.nih.gov/pubmed/34948083
http://dx.doi.org/10.3390/ijms222413288
_version_ 1784622344142061568
author Demyanets, Svitlana
Stojkovic, Stefan
Huber, Kurt
Wojta, Johann
author_facet Demyanets, Svitlana
Stojkovic, Stefan
Huber, Kurt
Wojta, Johann
author_sort Demyanets, Svitlana
collection PubMed
description In this review, we focus on the actual understanding of the role of IL-33 in vascular biology in the context of the historical development since the description of IL-33 as a member of IL-1 superfamily and the ligand for ST2 receptor in 2005. We summarize recent data on the biology, structure and signaling of this dual-function factor with both nuclear and extracellular cytokine properties. We describe cellular sources of IL-33, particularly within vascular wall, changes in its expression in different cardio-vascular conditions and mechanisms of IL-33 release. Additionally, we summarize the regulators of IL-33 expression as well as the effects of IL-33 itself in cells of the vasculature and in monocytes/macrophages in vitro combined with the consequences of IL-33 modulation in models of vascular diseases in vivo. Described in murine atherosclerosis models as well as in macrophages as an atheroprotective cytokine, extracellular IL-33 induces proinflammatory, prothrombotic and proangiogenic activation of human endothelial cells, which are processes known to be involved in the development and progression of atherosclerosis. We, therefore, discuss that IL-33 can possess both protective and harmful effects in experimental models of vascular pathologies depending on experimental conditions, type and dose of administration or method of modulation.
format Online
Article
Text
id pubmed-8707059
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87070592021-12-25 The Paradigm Change of IL-33 in Vascular Biology Demyanets, Svitlana Stojkovic, Stefan Huber, Kurt Wojta, Johann Int J Mol Sci Review In this review, we focus on the actual understanding of the role of IL-33 in vascular biology in the context of the historical development since the description of IL-33 as a member of IL-1 superfamily and the ligand for ST2 receptor in 2005. We summarize recent data on the biology, structure and signaling of this dual-function factor with both nuclear and extracellular cytokine properties. We describe cellular sources of IL-33, particularly within vascular wall, changes in its expression in different cardio-vascular conditions and mechanisms of IL-33 release. Additionally, we summarize the regulators of IL-33 expression as well as the effects of IL-33 itself in cells of the vasculature and in monocytes/macrophages in vitro combined with the consequences of IL-33 modulation in models of vascular diseases in vivo. Described in murine atherosclerosis models as well as in macrophages as an atheroprotective cytokine, extracellular IL-33 induces proinflammatory, prothrombotic and proangiogenic activation of human endothelial cells, which are processes known to be involved in the development and progression of atherosclerosis. We, therefore, discuss that IL-33 can possess both protective and harmful effects in experimental models of vascular pathologies depending on experimental conditions, type and dose of administration or method of modulation. MDPI 2021-12-10 /pmc/articles/PMC8707059/ /pubmed/34948083 http://dx.doi.org/10.3390/ijms222413288 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Demyanets, Svitlana
Stojkovic, Stefan
Huber, Kurt
Wojta, Johann
The Paradigm Change of IL-33 in Vascular Biology
title The Paradigm Change of IL-33 in Vascular Biology
title_full The Paradigm Change of IL-33 in Vascular Biology
title_fullStr The Paradigm Change of IL-33 in Vascular Biology
title_full_unstemmed The Paradigm Change of IL-33 in Vascular Biology
title_short The Paradigm Change of IL-33 in Vascular Biology
title_sort paradigm change of il-33 in vascular biology
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707059/
https://www.ncbi.nlm.nih.gov/pubmed/34948083
http://dx.doi.org/10.3390/ijms222413288
work_keys_str_mv AT demyanetssvitlana theparadigmchangeofil33invascularbiology
AT stojkovicstefan theparadigmchangeofil33invascularbiology
AT huberkurt theparadigmchangeofil33invascularbiology
AT wojtajohann theparadigmchangeofil33invascularbiology
AT demyanetssvitlana paradigmchangeofil33invascularbiology
AT stojkovicstefan paradigmchangeofil33invascularbiology
AT huberkurt paradigmchangeofil33invascularbiology
AT wojtajohann paradigmchangeofil33invascularbiology